je.st
news
Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO
2015-06-05 15:01:16| Biotech - Topix.net
It's weird, somewhat inappropriate and definitely risky for Biomarin given its DMD drug drisapersen is currently under FDA review. Sarepta Therapeutics If you're unsure what Steven is referring to, Biomarin and PTC Therapeutics are co-sponsoring an investor "symposium" on June 22 in New York City titled, Advances in Duchenne Muscular Dystrophy Natural History and Biomarkers .
Tags: cart
trouble
drama
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||